How to Cite
Abstract
DUSP9 / MKP-4 belongs to a subclass of bispecific protein phosphatases, which, by dephosphorylation of MAP kinases (ERK1 / 2, p38 and JNK), negatively regulate the activity of MAP kinase cascades. Hyperactivation of MAP kinase cascades is observed in many different cancer types, including kidney cancer. We have previously found that in human clear cell renal cell carcinoma (ccRCC) DUSP9 is downregulated. In this study, using the semi-quantitative RT-PCR method, we evaluated the expression level of DUSP9 in tumors of patients with different stages of renal cell carcinoma of three histological variants: ccRCC (26 samples), papillary (2 samples) and chromophobic (1 sample). For each tumor 3 distantly located pieces were analyzed. We showed that DUSP9 mRNA level was significantly reduced in all three pieces of each tumor compared with normal tissue. Promoter hypermethylation may be one mechanism of gene repression in cancer. Using the DNA demethylating agent 5-Aza-2'-deoxycytidine and RCC cell lines we showed a correlation between the mRNA level and methylation level of the promoter region of DUSP9 gene. We then analyzed methylation level of DUSP9 promoter in 31 clinical samples of RCC (11 female and 20 male patients). It was increased in 10 out of 11 female RCC. In men, the methylated alleles of DUSP9 were not detected in either tumor or paired normal specimens. The results of our study indicate that DUSP9 transcriptional repression is an early event in kidney carcinogenesis and that DUSP9 expression in RCC can be regulated epigenetically via DNA methylation of the gene promoter, in a sex-related manner. They also indicate the existence of alternative mechanisms of inactivation of the DUSP9 gene in RCC.
References
Cheburkin YV., Knyazeva Ю., Peter s. et al. Molecular portrait of human kidney carcinomas: the cDNA microarray profiling of kinases and phosphatases involved in the cell signaling control//Molecular biology. -2002. -Vol. 36. -№ 3. -P. 376-384.
Dhillon A.S., Hagan S., Rath 0., Kolch W. MAP kinase signalling pathways in cancer//Oncogene. -2007. -Vol. 26. -P. 3279-90.
Ferlay J., Soerjomataram I., Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012//International journal of cancer. -2015. -Vol. 136. -№ 5. -P. E359-E386.
Gerlinger M. Rowan A. J., Horswell S. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing//New England journal of medicine. -2012. -Vol. 366. -№ 10. -P 883-892.
Jenner S., Wiedorn K.H. and Techel D. Development of a DUSP9 methylation screening assay//Pathol Oncol Res. -2015. -Vol. 21. -P 123-30.
Liu J., Ni W., Xiao M. et.al. Decreased expression and prognostic role of mitogen-activated protein kinase phosphatase 4 in hepatocellular carcinoma//J. Gastrointest Surg. -2013. -Vol. 17. -P. 756-765.
Liu Y, Lagowski J., Sundholm A. et al. Microtubule disruption and tumor suppression by mitogen-activated protein kinase phosphatase 4//Cancer Res. -2007. -Vol. 67. -P 10711-10719.
Low H. B. and Zhang Y: Regulatory Roles of MAPK Phosphatases in Cancer//Immune Netw. -2016. -Vol. 16. -P 85-98.
Muda M., Boschert U., Smith A. et al. Molecular cloning and functional characterization of a novel mitogen-activated protein kinase phosphatase, MKP-4//J. Biol. Chem. -1997. -Vol. 272. -P 5141-5151.
Vaissire T., Hung R. J., Zaridze D. et al. Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors//Cancer Res. -2009. -Vol. 69. -P. 243-252.
Wiencke J. K., Zheng S., Lafuente A. et al. Aberrant methylation of p16INK4a in anatomic and gender-specific subtypes of sporadic colorectal cancer//Cancer Epidemiol. Biomarkers Prev. -1999. -Vol. 8. -P. 501506.
Wu F., Lv T, Chen G. et al. Epigenetic silencing of DUSP9 induces the proliferation of human gastric cancer by activating JNK signaling//Oncol. Rep. -2015. -Vol. 34. -P 121-128.
Wu S., Wang Y, Sun L. et al. Decreased expression of dual-specificity phosphatase 9 is associated with poor prognosis in clear cell renal cell carcinoma//BMC Cancer. -2011. -Vol. 26. -P. 413-420.
Xiong Z. and Laird P W. COBRA: a sensitive and quantitative DNA methylation assay//Nucleic acids research. -1997. -Vol. 25. -№ 12. -P 2532-2534.
Yap T. A., Gerlinger M., Futreal P. A. et al. Intratumor heterogeneity: seeing the wood for the trees//Sci. Transl. Med. -2012. -Vol. 4. -Issue 127. -P 127ps10.
Zhou L., Chen J., Li Z. et al. Integrated profiling of microRNAs and mRNAs: microRNAs located on Xq27.3 associate with clear cell renal cell carcinoma//PLoS One. -2010. -Vol. 5. -P e15224.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2019